Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1High Grade Serous Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 26Paclitaxel 25Carboplatin 19Bevacizumab 13Specimen Handling 11Magnetic Resonance Spectroscopy 9Doxorubicin 8Cisplatin 8Taxes 7Biopsy 7olaparib 6lenvatinib 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Megestrol Acetate 5Letrozole 5Gemcitabine 5Docetaxel 5trastuzumab deruxtecan 4Trastuzumab 4Tirzepatide 4Progestins 4Medroxyprogesterone Acetate 4Fluorouracil 4palbociclib 3ipatasertib 3atezolizumab 3abemaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × ceralasertib × 90 days × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡